4.2 Article

Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014

期刊

DIABETES THERAPY
卷 8, 期 4, 页码 863-873

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s13300-017-0280-5

关键词

Diabetes; Glycemic control; United States; Trends

资金

  1. Intarcia Therapeutics

向作者/读者索取更多资源

Introductions: Previous research has found that the percentage of US adults with diabetes achieving a glycated hemoglobin (HbA1c) target of < 7.0% with currently available treatments has been fairly constant from 2003 to 2010, remaining at just over 50% [1]. The objective of this study was to compare the most recent data (2011-2014) with earlier data to track progress on HbA1c target achievement, for both the general target of < 7.0% and inferred individualized targets based on age and the presence of complications. Methods: Data from 2677 adults with self-reported diabetes from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2014 were examined to determine the percentage of adults who achieved HbA1c targets of < 7% and an individualized target based on age and comorbidities. National estimates are reported by using weights that account for the complex sampling design of the NHANES. Results: The percentage of people with diabetes and HbA1c < 7.0% slightly declined from 52.2% (95% CI 48.7-55.7%) to 50.9% (95% CI 47.2-54.7%) between the two most recent waves of data. Achievement of individualized targets declined from 69.8% (95% CI 66.5-73.0%) to 63.8% (95% CI 60.1-67.5%). The percentage with HbA1c > 9.0% increased from 12.6% (95% CI 10.5-14.8%) to 15.5% (95% CI 12.9-18.2%). Achievement of individualized targets varied by age group and presence of comorbidities, but exhibited similar trends as general target achievement. Conclusions: Despite the development of many new medications to treat diabetes during the past decade, the proportion of patients achieving glycemic control targets has not improved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据